Results 61 to 70 of about 1,183,713 (344)

Deferoxamine promotes recovery of traumatic spinal cord injury by inhibiting ferroptosis

open access: yesNeural Regeneration Research, 2019
Ferroptosis is an iron-dependent novel cell death pathway. Deferoxamine, a ferroptosis inhibitor, has been reported to promote spinal cord injury repair.
Xue Yao   +14 more
semanticscholar   +1 more source

Spinal Cord Regeneration

open access: yesScience, 1996
A paper in this week's issue of Science (Cheng and Olson, p. 510 ) reports the first hint that truly functional regeneration of the adult spinal cord may be possible, at least in the rat. In his Perspective, Young describes why this demonstration of regeneration is so important but cautions ...
openaire   +6 more sources

COMMOTION OF SPINAL CORD [PDF]

open access: yesThe Journal of Nervous and Mental Disease, 1919
n ...
Roussy, G.-R., Cornil, L.
openaire   +2 more sources

3D MRI Tract‐Specific Spinal Cord Lesion Pattern Improves Prediction of Distinct Neurological Recovery

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To distinguish lateralized motor‐ and sensory‐tract damage after acute spinal cord injury (SCI) and explore its predictive power for motor and sensory recovery. Methods Thirty‐five SCI patients (two female) from a multi‐center data set (placebo‐arm of the Nogo‐A‐Inhibition in SCI trial) underwent routine T2‐weighted sagittal MRI ...
Lynn Farner   +7 more
wiley   +1 more source

Feasibility of visual instrumented movement feedback therapy in individuals with motor incomplete spinal cord injury walking on a treadmill

open access: yesFrontiers in Human Neuroscience, 2014
Background: Incomplete spinal cord injury (iSCI) leads to motor and sensory deficits. Even in ambulatory persons with good motor function an impaired proprioception may result in an insecure gait.
Daniel eSchließmann   +7 more
doaj   +1 more source

Spinal Cord Stimulation for Spinal Cord Injury

open access: yes, 2023
Spinal cord injury is a medically complex and life-disrupting condition, associated with very high mortality rates (early death rates after admission range from 4 to 20%). In addition, it’s complicated subsequent severe disability due to the development of early or late complications.
Emil, Isagulyan,   +2 more
openaire   +2 more sources

SARS‐CoV‐2 Is Linked to Brain Volume Loss in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The impact of SARS‐CoV‐2 infection on brain and spinal cord pathology in patients with multiple sclerosis (pwMS) remains unclear. We aimed to describe changes in brain lesion activity and brain and spinal cord volumes following SARS‐CoV‐2 infection.
Tomas Uher   +12 more
wiley   +1 more source

Effects of pedicle subtraction osteotomy on aortic morphology and hemodynamics in ankylosing spondylitis with kyphosis: a finite element analysis study

open access: yesScientific Reports
Osteotomy can correct kyphosis, restore the spinal sequence, and restore the healthy appearance of a patient. However, the aorta is stretched during pedicle subtraction osteotomy (PSO), and some surgeons are concerned about aortic injury.
Weiran Hu   +5 more
doaj   +1 more source

Beyond treatment of chronic pain: a scoping review about epidural electrical spinal cord stimulation to restore sensorimotor and autonomic function after spinal cord injury

open access: yesNeurological Research and Practice, 2023
Epidural electrical epinal cord stimulation (ESCS) is an established therapeutic option in various chronic pain conditions. In the last decade, proof-of-concept studies have demonstrated that ESCS in combination with task-oriented rehabilitative ...
Antonia Luz   +3 more
doaj   +1 more source

Factors for Rituximab Refractoriness in AQP4‐IgG+ NMOSD: A Cohort Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition of the central nervous system (CNS), often associated with aquaporin‐4 antibodies (AQP4‐IgG). Rituximab, a CD20+ B‐cell depleting monoclonal antibody, is widely used as first‐line therapy.
Mariano Marrodan   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy